Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

Female Sexual Arousal Disorder Clinical Trial

— RESPOND  

Official title:

A Phase 2b, Multi-Center, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sildenafil Cream, 3.6% in Premenopausal Patients With Female Sexual Arousal Disorder (FSAD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04948151
• Other study ID #: SST-6006-013
• Status: Recruiting
• Phase: Phase 2
• Start date: June 28, 2021
• Est. completion date: December 15, 2021

Study information

• Verified date: June 2021
• Source: Strategic Science & Technologies, LLC
• Contact: Kathy Cornell
• Phone: 774-473-4414
• Email: kcornell[@]strategicscience.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is looking to minimize side effects, while maintaining and potentially improving the therapeutic benefit to patients suffering from Female Sexual Arousal Disorder by providing a topical preparation of Sildenafil locally to the vulvar-vaginal tissue.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 440
• Est. completion date: December 15, 2021
• Est. primary completion date: December 15, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria - For Patient Eligibility

1. Patient must be a premenopausal woman, 21 years or older. a. Transgender individuals assigned a female gender at birth will be permitted to enroll provided they are not currently undergoing hormone treatment, have not undergone gender reassignment surgery and do not intend to for the duration of the study.

2. Patient is fluent in the English language.

3. Patient is capable of understanding and complying with the protocol and agrees to sign the informed consent document.

4. Patient has been in a stable, monogamous, relationship that was secure and communicative, for at least 6 months prior to Visit 1. The relationship is with one sexual partner, who is sexually functional, both psychologically and physically. The partner will be consistent and available throughout the duration of the study.

5. Based on the clinical interview, in their past, patient had experienced 'normal' sexual function for at least 2 years or longer. Patient has had sexual activity at least two times each month during the last 6 months and agrees to have sexual activity at least two times each month for the duration of the study). Sexual activity can include any activity which may result in sexual stimulation or sexual pleasure e.g., intercourse, caressing, foreplay, masturbation, and oral sex. a. Patients who have experienced a recent major life stress (e.g., loss of income, death of a family member) or relationship discord that could interfere with sexual activity (except distress related to FSAD) will be excluded.

6. Women of childbearing potential must agree to continue using an acceptable form of birth control during the study and agree to continue to stay on their dose of birth control throughout the duration of the study. Birth control is not required for confirmed same sex couples, couples with confirmed vasectomy or couples with confirmed tubal ligation.

1. Acceptable forms of birth control include the following: intrauterine system [IUS], progestin and/or estrogen-containing hormonal oral contraceptives, contraceptive patch, contraceptive implant, contraceptive injection, or the copper-containing intrauterine device (IUD). Patients must be using the progestin and or estrogen-containing hormonal oral contraceptives or contraceptive patch for least 6 months prior to Visit 1 without clinically significant complications in the opinion of the Investigator. Patients must be using the IUS, IUD, contraceptive implant, or contraceptive injection for at least 3 months prior to Visit 1 without clinically significant complications in the opinion of the Investigator.

2. Vaginal forms of contraception such as contraceptive foams/gels, diaphragms, penile or vaginal condoms, contraceptive vaginal rings, and are not considered acceptable methods of birth control in this study.

3. While latex and polyisoprene condoms are not an acceptable form of contraception, they may be used for the prevention of sexually transmitted infections.

7. Patient has a body mass index (BMI) from 18 to 35 kg/m2, inclusive.

8. Patient has had a Pap smear performed within three years prior to Visit 1 and can provide documentation indicating normal test results (based on current guidelines as published by the U.S. Preventive Services Task Force). a. If the patient cannot provide documentation, a Pap smear will be performed at Visit 1. Patients with abnormal findings will be excluded from study participation and be referred for follow-up medical care as appropriate.

9. Patient is medically healthy with no clinically significant medical history, physical examination, gynecological history and examination, laboratory profiles (e.g., hematology, urinalysis), vital signs (e.g., uncontrolled hypertension), or ECGs, as deemed by the Investigator.

1. Patients who have clinically significant ECG abnormalities at Visit 1 as confirmed by the Investigator will be excluded.

2. Patients with controlled, treated hypertension (<140/90 mmHg) on up to two medications (excluding alpha blockers and nitrates) with a stable dose for the past 6 months will be considered eligible.

3. Patients with controlled, treated thyroid disease on a stable medication and dose for the past 6 months will be considered eligible. TSH must be within normal range (confirmed by laboratory test).

10. The participant must agree to not use vaginal hormone therapy (e.g., vaginal estrogen, intravaginal prasterone), vaginal or vulvar lubricants, spermicides, creams or gels, contraceptive foams or vaginal douche products throughout the study period.

1. Women who self-report abnormal physiological vaginal discharge will be excluded until abnormal physiological discharge resolves.

2. Patients using systemic (transdermal or oral) therapy must be on a stable dose for at least 6 months prior to Visit 1.

11. Patient must have a total score on the FSDS-DAO >18 through visit 4. Exclusion Criteria - For Patient Eligibility

1. Patient is nursing or pregnant (based on positive serum pregnancy test), wishes to become pregnant or begin nursing during the study period or was pregnant or nursing within 6 months prior to Visit 1.

2. Patient has more than one sexual partner.

3. Patient is postmenopausal (surgically induced or natural) meeting any of the following

criteria:

1. Bilateral oophorectomy.

2. 12 months of spontaneous amenorrhea

3. 6 months of spontaneous amenorrhea with serum FSH levels >40mIU/mL (except for those women on hormone replacement therapy)

4. Patient has any disorder or a history of any disorder that may prevent the successful completion of the study in the opinion of the Investigator.

5. Patient has a significant cardiovascular, hepatic, metabolic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, genitourinary, or other unstable medical condition that would contraindicate administration of study medication, interfere with study evaluation, limit study participation, or confound the interpretation of study results in the opinion of the Investigator.

6. Patient has a history of unresolved sexual trauma or abuse that is contributing to any sexual dysfunction problem (desire, arousal, orgasm, etc.) as determined by the clinical interview.

7. Patient with any history of active peptic ulcers or clinically significant bleeding disorders.

8. Patient with a history of clitoral priapism or conditions which may predispose them to clitoral priapism (such as sickle cell anemia, multiple myeloma, or leukemia).

9. Patients with a history of myocardial infarction, stroke, or life-threatening arrhythmia within 6 months prior to Visit 1; patients with resting hypotension (BP <90/50 mmHg); or any history of coronary disease causing angina; or congestive heart failure requiring medical intervention; patients with underlying conditions which can be particularly sensitive to the actions of vasodilators including patients with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and patients with impaired autonomic control of blood pressure, or for those for which sexual activity is inadvisable due to their underlying cardiovascular status.

10. Patient with a history of hearing loss (unless born completely deaf).

11. Patient has retinitis pigmentosa, even if the patient feels clinically well at the time of Visit 1. Patients with retinitis pigmentosa will be identified by specifically asking whether they have the condition, if there are visual signs and symptoms of the condition (including questioning patients as to whether they have difficulty seeing at night or in low light, and if they have any visual field deficits that indicate a loss of peripheral or central vision), or if there is a family history.

12. Patient has a history of orthostatic hypotension or orthostatic hypotension which is present at Visit 1, defined as a drop in systolic blood pressure = 20 mm Hg, a drop in diastolic blood pressure = 10 mm Hg, an increase in pulse by 20 beats per minute or experiencing lightheadedness or dizziness at 1 or 3 minutes after the change in position from supine to standing.

13. Patient has a primary complaint of anorgasmia, vaginismus, low desire, or any other primary sexual complaint aside from problems with genital arousal, as determined by the clinical interview.

14. Patient has untreated dyspareunia, vulvovaginal infection or inflammation, inflammatory disorders of the vulva or vagina, vestibulodynia, clitorodynia, or symptomatic vulvovaginal atrophy (defined as women having =5% of superficial cells on vaginal smear at baseline,

15. Patient has undergone major pelvic or abdominal surgery that may have caused nerve damage, including, vulvectomy, colostomy, cystostomy, hysterectomy and bladder neck suspension.

16. Patients with comorbid conditions that may cause underlying neurological impairment (i.e., Type 1 or Type 2 diabetes, metabolic syndrome, stroke, myasthenia gravis, multiple sclerosis or spinal cord damage) will be excluded. a. Patients who are symptomatic of peripheral neuropathy will be excluded.

17. Patients with pelvic nerve damage secondary to trauma will be excluded.

18. With the exception of anxiety and depression, patient has any current and/or previously reported diagnoses of DSM-IV-TR axis I disorders (e.g., schizophrenia, bipolar disorder) including delirium, dementia and amnestic disorders.

1. Patients diagnosed with anxiety or depression must be controlled, as determined by the Investigator, and if on a medication (i.e., SSRIs, SNRIs, buspirone, bupropion, and benzodiazepines), on a stable dose for at least the past 6 months.

2. Patients must have a total score <10 indicating mild depression on the Patient Health Questionnaire-8 (PHQ-8, Appendix G) (a screening and assessment instrument for depression).

3. Patients must have a total score <6 indicating mild anxiety on the Generalized Anxiety Disorder (GAD-7, Appendix H) (a screening and assessment instrument for anxiety).

4. Patients who have any history of anti-psychotic therapy within the last year will be excluded.

19. Patients that have a history of gynecological cancer or are under active treatment (or recently completed treatment within the last 6 months) for any cancer which in the Investigator's judgement would interfere with the patient's ability to successfully complete the study will be excluded.

1. Patients who have been previously treated for dysplasia (precancerous changes) may be included as long as the patient received localized treatment (e.g., cryosurgery or laser).

2. Patients with a history of radiation to the pelvis will be excluded.

20. Patient has any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article in the opinion of the Investigator.

21. Patient self-reports a history of substance abuse within two years prior to Visit 1 or exhibits signs of current substance abuse based on Investigator judgement.

22. Patient self-reports a history of alcohol abuse in the two years prior to Visit 1 or exhibits signs of current alcohol abuse based on Investigator judgement.

23. Patient has a history of non-arteritic ischemic optic neuropathy (NAION) or any underlying NAION risk factors.

24. Patient whose sexual function was affected (enhanced or worsened) by any medication within 28 days before Visit 1 and at any time prior to the No Drug Run-in Period of the study.

25. Patient is currently receiving treatment or has received treatment within 1 month (28 days) prior to Visit 1 of any of the following medications: guanylate cyclase stimulators (e.g., Riociguat), clonidine, strong CYP3A4 inhibitors, nitric oxide donors, such as organic nitrates or organic nitrites, and alpha blockers. a. Patients who are currently receiving treatment or have received treatment in the past 3 months for FSAD symptoms, pharmacologic (e.g., PDE5 inhibitors in any form except Sildenafil Cream, 3.6% or other experimental therapies used to enhance the arousal response) or non-pharmacologic treatment (e.g., sex therapy), will also be excluded.

26. Patient has positive findings from the urine drug screen (e.g., amphetamines, barbiturates, cocaine, methadone, and opiates). Patients who test positive for amphetamines but are being treated for ADHD with a confirmed legal prescription will be allowed to participate.

27. Patient has positive findings for sexually transmitted infection (gonorrhea, trichomoniasis, chlamydia), and human immunodeficiency virus (HIV) antibodies.

28. Patient reports having an outbreak (blisters, warts, or vesicles) due to any of the following sexually transmitted diseases: genital herpes or HPV at any time point in the past three months.

29. Patient has participated in any clinical research study evaluating another investigational drug or therapy within 30 days before Visit 1 (or 6 half-lives of the investigational agent, whichever is longer) and agrees not to participate in another clinical research study throughout the duration of the study.

30. Patient has any clinically significant abnormal findings on vulvar-vaginal examination performed during the physical and gynecological exams at Visit 1 (e.g., genital skin breaks, irritation, dermatoses, or lesions).

31. Patient currently has moderate to severe current vaginitis, a vaginal infection including bacterial vaginosis, a yeast infection or the presence of yeast based on the Nucleic Acid Amplification (NAAT).

1. If the patient has a vaginal infection or a positive test for yeast during the screening visit, they may be treated, and the screening visit rescheduled.

2. If the patient develops a vaginal infection following enrollment into the study, study drug will be withheld, and the patient will be treated for the infection. If the infection cannot be resolved within two weeks the patient will be withdrawn from the study. Treatment of vaginal infections will be allowed twice following enrollment. If the patient develops a third vaginal infection they will be withdrawn from the study.

32. Patient has a pelvic or urinary tract infection.

1. If the patient has a urinary tract infection during the screening visit, they may be treated, and the screening visit rescheduled.

2. If the patient develops a urinary tract infection following enrollment into the study, study drug will be withheld, and the patient will be treated for the infection. If the infection cannot be resolved within two weeks the patient will be withdrawn from the study. Treatment of urinary tract infections will be allowed twice following enrollment. If the patient develops a third urinary tract infection they will be withdrawn from the study.

33. Patient self-reports a known hypersensitivity or adverse reaction to any ingredients in the Investigational Product (IP).

34. The patient is an immediate family member, a study site employee, or is in a dependent relationship with a study site employee or anyone who is involved in the conduct of the study (e.g., spouse, parent, child, sibling) or may consent under duress.

Related Conditions & MeSH terms

• Disease
• Female Sexual Arousal Disorder
• Sexual Dysfunction, Physiological
• Sexual Dysfunctions, Psychological

Intervention

Drug:
• Sildenafil
Patients will apply 2-gram applications up to 9 times per month.
• Placebo
Patients will apply 2-gram applications up to 9 times per month

Locations

Country	Name	City	State
United States	AGILE Clinical Research Trials	Atlanta	Georgia
United States	South Florida Medical Research	Aventura	Florida
United States	Boston Clinical Trials	Boston	Massachusetts
United States	ClinSearch	Chattanooga	Tennessee
United States	Great Lakes Clinical Trials	Chicago	Illinois
United States	Velocity Clinical Research - Cleveland (Rapid Medical Research)	Cleveland	Ohio
United States	Aventiv Research, inc.	Columbus	Ohio
United States	Southern Institute for Women's Sexual Health	Covington	Louisiana
United States	iResearch Atlanta	Decatur	Georgia
United States	Downtown Women's Healthcare	Denver	Colorado
United States	AMR Fort Myers	Fort Myers	Florida
United States	Collaborative Neuroscience Network	Garden Grove	California
United States	TMC Life Research	Houston	Texas
United States	Rosemark Women Care Specialists	Idaho Falls	Idaho
United States	Clinical Neuroscience Solutions-Orlando	Jacksonville	Florida
United States	Essential Women's Health Associates	Las Vegas	Nevada
United States	Office of Doctor Rex G. Mabey Junior	Las Vegas	Nevada
United States	Women's Health Research Center	Lawrenceville	New Jersey
United States	Maximos Obstetrics and Gynecology	League City	Texas
United States	Praetorian Pharmaceutical Research	Marrero	Louisiana
United States	University Hospitals Landerbrook	Mayfield Heights	Ohio
United States	Clinical Neuroscience Solutions - Memphis	Memphis	Tennessee
United States	Medical Research Center of Memphis	Memphis	Tennessee
United States	New Age Medical Research Corporation	Miami	Florida
United States	New Jersey Urology - Bloomfield	Millburn	New Jersey
United States	Coastal Clinical Research	Mobile	Alabama
United States	The Center for Specialized Women's Health	Morristown	New Jersey
United States	Urology Associates - Nashville	Nashville	Tennessee
United States	Coastal Connecticut Research, LLC	New London	Connecticut
United States	Suncoast Clinical Research - Pasco County	New Port Richey	Florida
United States	Health Research of Hampton Roads, Inc.	Newport News	Virginia
United States	Tidewater Clinical Research	Norfolk	Virginia
United States	Coastal Carolina Research Center	North Charleston	South Carolina
United States	Healthcare Clinical Data, Inc.	North Miami	Florida
United States	Rivus Wellness & Research Institute	Oklahoma City	Oklahoma
United States	Omaha OB GYN Associates, P.C.	Omaha	Nebraska
United States	Quality Clinical Research	Omaha	Nebraska
United States	NRC Research Institute	Orange	California
United States	CNS Healthcare	Orlando	Florida
United States	Precision Clinical Trials-Arizona	Phoenix	Arizona
United States	Suffolk Obstetrics and Gynecology	Port Jefferson	New York
United States	Women's OB-GYN, P.C. dba Saginaw Valley Medical	Saginaw	Michigan
United States	Clinical Trials of Texas	San Antonio	Texas
United States	Medical Center for Clinical Research - San Diego	San Diego	California
United States	Seattle Women's Health Research - Gynecology	Seattle	Washington
United States	Schuster Medical Research Institute	Sherman Oaks	California
United States	Visions Clinical Research -Tucson	Tucson	Arizona
United States	Velocity Clinical Research, Providence	Warwick	Rhode Island
United States	Intimmedicine Specialists	Washington	District of Columbia
United States	Comprehensive Clinical Research, LLC	West Palm Beach	Florida
United States	Cypress Medical Research Center	Wichita	Kansas

Sponsors (2)

Lead Sponsor	Collaborator
Strategic Science & Technologies, LLC	Daré Bioscience, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SFQ28 (AS) - 28 Day Recall	Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the Arousal-Sensation Domain of the SFQ28.	SFQ28 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.
Primary	FSDS-DAO (Q14) - 28 Day Recall	Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the score for feeling concerned by difficulties with sexual arousal - Item #14 only of the FSDS-DAO.	Q14 score at the end of the Single-Blind Placebo Run-In to the end of the 12-Week Double-blind Dosing period.
Secondary	Arousal Diary (SSE)	Evaluating the efficacy of Sildenafil Cream, 3.6% measured by change from baseline to end of study in the number of Satisfactory Sexual Events, question #11 in teh ARousal Diary.	measured by daily prompt within 24hrs after each sexual event during the Single-Blind Placebo Run-In compared to the last 4 weeks of the Double-Blind Dosing Period.